first opinion
What real-world data can do for patients and providers

Adobe
New drugs are entering the clinic faster than ever. The FDA's Breakthrough Therapy designation program is an example of regulatory innovation that helps speed drugs to market, writes Boston-based health and life sciences consultant Jenna Phillips — but it also means that there's less time to train clinicians on best practices with a new therapy.
In a new First Opinion, Phillips argues that real-world clinical data can offer insights about how to best use new medicines. It can help pinpoint clinician and patient experiences with new drugs: Real-world data on GLP-1 weight loss drugs, for example, shows patients present to the emergency department with side effects like gastrointestinal distress. Read more about how these kind of insights could help health workers improve care.
artificial intelligence
Scientists call for a strategic council to guide AI use
The advent of increasingly powerful AI algorithms has scientists both excited and nervous. Artificial intelligence offers new research opportunities and problem-solving abilities — but it also opens the door to new kinds of ethical violations, as a new editorial in the Proceedings of the National Academy of Sciences points out.
The authors discuss five ways to help maintain scientific integrity in the context of AI. Scientists should be accountable for the content or inferences they might draw from generative models, for one, and AI-generated work or data should be clearly documented. AI should also be vetted to avoid causing harm, including perpetuating biases — and to lead the way, the authors suggest the National Academies create a "strategic council on the responsible use of artificial intelligence in science."
No comments